| Primary information |
|---|
| sequence ID | Seq_5375 |
| Peptide sequence | MGKVVNPTQK |
| CancerPDF_ID | CancerPDF_ID9497, CancerPDF_ID9498, CancerPDF_ID9982, |
| PMID | 21533267,21533267,21805675 |
| Protein Name | Alpha-1-antitrypsin,Alpha-1-antitrypsin,Alpha-1-antitrypsin |
| UniprotKB Entry Name | A1AT_HUMAN,A1AT_HUMAN,A1AT_HUMAN |
| Fluid | Serum,Serum,Urine |
| M/Z | 551.29,559.3,1101.5892 |
| Charge | 2,2,NA |
| Mass (in Da) | NA,NA,NA |
| fdr | NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,MALDI-TOF |
| Peptide Identification technique | LC/MS/MS,LC/MS/MS,MALDI-TOF-MS |
| Quantification Technique | Multiple Reaction Monitoring,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | 1.49,1.49,1 |
| CancerPDF_ID | CancerPDF_ID9497, CancerPDF_ID9498, CancerPDF_ID9982, |
| p-Value | NA,NA,NA |
| Software | MASCOT,MASCOT,NA |
| Length | 10,10,10 |
| Cancer Type | Lung adenocarcinoma,Lung adenocarcinoma,Muscle-invasive bladder cancer |
| Database | Swissprot Database (57.4),Swissprot Database (57.4),SwissProt Database |
| Modification | NA,Oxidation,NA |
| Number of Patients | 62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control,751 bladder cancer and 127 control |
| Regulation | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal",Differentially expressed between cancer vs normal samples |
| Validation | MRM-based validation of 19 candidates,MRM-based validation of 19 candidates,Mann-Whitney tests and areas under receiver-operator characteristic |
| Sensitivity | NA,NA,NA |
| Specificity | NA,NA,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | 439314
|